Woebot Healthmaker of an AI-powered mental health chatbot announced Tuesday that it has raised $9.5 million from Leaps by Bayer.
The strategic investment comes about eight months after the company said it had scored $90 million in Series C financing. Last year, Woebot received the FDA Breakthrough Device Designation for its digital therapeutic treatment of postpartum depression.
“Woebot Health’s mission and products align well with our jumps number 5 and 10 † to protect the brain and mind and transform health with data,” Dr. Jürgen Eckhardt, head of Leaps by Bayer, said in a statement.
“With its deep focus on clinical evidence and unique AI-based platform and products, Woebot Health is forging a new frontier in behavioral health at a critical time in our world. We are excited to support efforts to make technology-enabled continuous care a reality for everyone.”
Founded in 2017Woebot estimates his total raise at $123.5 million.
Open loopwhich staffs and supports digital health companies launching virtual health services, raised $8 million in Series A funding.
The round was led by SpringTide Ventures with participation from ManchesterStory, Next Level Ventures, Panoramic Ventures, ISA Ventures and some strategic healthcare syndicates. OpenLoop said the Series A will bring the total raise to about $11 million.
The startup provides regulatory and legal assistance, staffing, telehealth infrastructure, administrative services and revenue cycle management to companies building virtual healthcare services. It says it will use the investment to expand its technical infrastructure and hire new staff members for its practice management and revenue cycle teams.
Digital Therapeutic Company on Prescription metaMe Health has raised $2.2 million in a bridging financing round led by Hyde Park Angels with the participation of individual investors.
The company will use the funding to prepare for the market introduction of Regulora, a digital prescription drug targeting the treatment of abdominal pain associated with irritable bowel syndrome in adults. Receiving the therapeutic FDA 510(k) approval late last year. metaMe said it plans to release Regulora in the second half of 2022.
“We are delighted to have HPA’s support as we prepare for the launch of Regulora,” CEO Tim Rudolphi said in a statement. “We believe Regulora is poised to change the lives of the millions of Americans who suffer from IBS. HPA’s support provides the capital and expertise we need to prepare for launch and to raise our Series A funding. to fetch.”